Login | Register

Bevacizumab Doesn’t Improve Survival In Some Older Lung Cancer Patients

A study published in the April 18 issue of JAMA, reveals that Medicare insured non-small cell lung cancer (NSCLC) patients aged 65+, who received bevacizumab, in addition to the standard chemotherapy regimen carboplatin and paclitaxel, did not have improved survival compared to patients who received carboplatin and paclitaxel alone...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *